US 12,454,558 B2
TFEB mutants and their use in the treatment and/or prevention of disorders that require the induction of the cellular autophagy-lysosomal system
Alejandro Rojas-Fernandez, Valdivia (CL); Patricia Burgos, Valdivia (CL); and Alexis González, Valdivia (CL)
Assigned to UNIVERSIDAD AUSTRAL DE CHILE, Valdivia (CL)
Appl. No. 17/604,321
Filed by UNIVERSIDAD AUSTRAL DE CHILE, Valdivia (CL)
PCT Filed Apr. 16, 2019, PCT No. PCT/CL2019/050028
§ 371(c)(1), (2) Date Oct. 15, 2021,
PCT Pub. No. WO2020/210921, PCT Pub. Date Oct. 22, 2020.
Prior Publication US 2022/0185854 A1, Jun. 16, 2022
Int. Cl. A61K 38/17 (2006.01); C07K 14/47 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/47 (2013.01) [A61K 38/00 (2013.01)] 7 Claims
 
1. Mutants of transcription factor EB also referred to as TFEB mutants,
wherein the mutants are constitutively active by inability to be modified by SUMO,
wherein amino acids of the mutants have been modified at at least two positions including lysine 219 and lysine 347 of a human TFEB.